OrganoTherapeutics

OrganoTherapeutics, founded in 2019 and headquartered in Luxembourg, is an innovative player in the Biopharma, Biotechnology, Life Sciences, and Pharmaceutical industries. With a focus on neurological disorders, the company leverages cutting-edge technology through human-specific midbrain organoids. Their slogan, "Using Midbrain Organoids for the development of new Therapeutics against Parkinson's Disease," encapsulates their mission.

The organization's primary goal is to uncover and develop drug candidates targeting Parkinson's disease. Their proprietary organoids are critical, accurately mimicking the disease's pathology, and providing a reliable platform for molecule screening against state-of-the-art 3D patient models.

With a recent infusion of early-stage venture capital from Khanu Management in August 2023, OrganoTherapeutics is poised for further growth. This financial backing could accelerate access to additional molecule libraries, enhancing their drug discovery pipeline.